3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Lymphoma
7
Lymphoma, Large B-Cell, Diffuse
5
Glioblastoma
5
Breast Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Carcinoma, Non-Small-Cell Lung
4
Multiple Myeloma
3
Lymphoma, Follicular
3
Leukemia, Myeloid, Acute
3
Gliosarcoma
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lung Neoplasms
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Erythroblastic, Acute
2
Leukemia
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Graft vs Host Disease
2
Glioma
2
Carcinoma, Renal Cell
2
Interventions
Pemetrexed
7
Cisplatin
7
Cyclophosphamide
5
pembrolizumab
4
fludarabine
4
Platinum
3
Drug Therapy
3
aldesleukin
2
Nivolumab
2
Ipilimumab
2
Interleukin-2
2
1,2-diaminocyclohexaneplatinum II citrate
2
vatalanib
1
spartalizumab
1
regorafenib
1
napabucasin
1
methoxyamine
1
fludarabine phosphate
1
enzalutamide
1
cediranib
1
avelumab
1
atezolizumab
1
anetumab ravtansine
1
Vorinostat
1
Thiostrepton
1
Tetrahydrouridine
1
Radiosurgery
1
Megestrol Acetate
1
Levoleucovorin
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Mesothelioma, Malignant
×
Vorinostat
×
Clear all
NCT01353482
2012-03-22
MESO-02
University College, London
Phase 1/2
Withdrawn